Clinical Genetic Test
offered by
GTR Test Accession: Help GTR000500217.1
Last updated in GTR: 2012-09-28
Last annual review date for the lab: 2022-10-27 Past due LinkOut
At a Glance
Hemolytic uremic syndrome, atypical, susceptibility to, 1; Mesangiocapillary glomerulonephritis, type II
Genes (8): Help
APLN (Xq26.1), C3 (19p13.3), CD46 (1q32.2), CFB (6p21.33), CFH (1q31.3), ...
Molecular Genetics - Sequence analysis of the entire coding region: Bi-directional Sanger Sequence Analysis
Not provided
Not provided
Not provided
Ordering Information
Offered by: Help
Genome Diagnostics Laboratory
View lab's website
Specimen Source: Help
Who can order: Help
  • Health Care Provider
Lab contact: Help
Leslie Steele, MSc, Co-ordinator
416-813-7200 ext 1
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
Requests are made from the referring health care provider through completion of the Molecular Genetics test requisition
Order URL
Test service: Help
Clinical Testing/Confirmation of Mutations Identified Previously
Confirmation of research findings
Test development: Help
Test developed by laboratory (no manufacturer test name)
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 2
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 8
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Total methods: 1
Method Category Help
Test method Help
Instrument *
Sequence analysis of the entire coding region
Bi-directional Sanger Sequence Analysis
* Instrument: Not provided
Clinical Information
Test purpose: Help
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
Novel variations are evaluated using a variety of algorithms including splice site analysis, sequence conservation within species and isoforms and functional estimation (i.e. SIFT, Polyphen, AlignGVGD & Mutation Taster). If the variation cannot be placed into a pathogenic or non-pathogenic state, further studies including evaluation of family members and/or assessing … View more

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help

Will the lab re-contact the ordering physician if variant interpretation changes? Help
No. They must contact us and want further information if they act on behalf of the patient
Recommended fields not provided:
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
PCR-based sequencing detects 99% of the reported mutations in the CFH, CFI, CFB, CFHR5, CD46, C3, APLN & THBD genes. The sensitivity of DNA sequencing is over 99% for the detection of nucleotide base changes, small deletions, insertions and indels in the region analyzed.
Proficiency testing (PT):
Is proficiency testing performed for this test? Help

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Software used to interpret novel variations Help
SIFT, POLYPHEN, Mutation Taster, Splicing Programs

Laboratory's policy on reporting novel variations Help
They are reported as such
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Category: Not Applicable
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.